Company Financials
Faron Pharmaceuticals OY Financials
Euro
business
Faron Pharmaceuticals OY Company Profile
Main Stock Listing
OMXH: FARON
Market Capitalization €119.1 Million as of July 1, 2024
Market Cap History
Valuations Metrics as of May. 5, 2024
| Trailing PE | |
| Forward PE | |
| Price to Sales TTM | € |
| Price to Book MRQ | € |
| Enterprise to Revenue | |
| Enterprise to EBITDA | -4.66 |
Financial Reports as of Dec. 31, 2023
Financials
| Fiscal Year Ends | 2023-12-31 |
| Most Recent Quarter | 2023-12-31 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Return on Assets TTM | -166.16% |
| Return on Equity TTM | 204.10% |
Income Statement
| Revenue TTM | €0 |
| Revenue per Share TTM | € |
| Quarterly Revenue Growth | % |
| Gross Profit TTM | €0 |
| EBITDA | €-28,371,000 |
| Net Income to Common TTM | €-30,944,000 |
| Diluted EPS TTM | €-0.48 |
| Quarterly Earnings Growth YoY | % |
Balance Sheet
| Total Cash MRQ | €6,875,000 |
| Total Cash per Share MRQ | €0.10 |
| Total Debt MRQ | € |
| Total Debt to Equity MRQ | -0.86 |
| Current Ratio MRQ | 0.59 |
| Book Value per Share MRQ | €-0.22 |
Cash Flow
| Operating Cash Flow TTM | €-23,806,000 |
| Levered Free Cash Flow TTM | €-12,882,375 |
FARON Stock Info as of May. 5, 2024
Stock Statistics
| Shares Outstanding | 72,007,504 |
| Float Shares | 41,825,064 |
| Avg 10 Volume | 70,462 |
| Avg 30 Volume | None |
| Shares Short | None |
| Short Ratio | |
| Short % of Shares | % |
| % Held by Insiders | 39.83% |
| % Held by Institutions | 12.53% |
Stock Price Summary
| Beta | -0.13 |
| Fifty Two Week Low | €1.35 |
| Fifty Two Week High | €4.59 |
| Fifty Two Week Change | -91.26% |
| Day 50 MA | €1.64 |
| Day 200 MA | €3.01 |
Dividends and Splits
| Forward Annual Dividend Rate | € |
| Forward Annual Dividend Yield | % |
| Trailing Annual Dividend Rate | €0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Dividend Date | |
| Ex Dividend Date | |
| Last Split Factor | |
| Last Split Date |